A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma - PASSION

Study identifier:D5890L00016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Comparison of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5mg, 1 Inhalation two times a day (b.i.d.) plus as needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults a -26-week, Randomized, Open-label, Parallel-group, Multicentre Study

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Symbicort TBH - Turbuhaler, beta-II-agonist, inhale steroid

Sex

All

Actual Enrollment

430

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Dec 2005
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2012 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria